Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Trial in Healthy Indonesian Women Ages 18-45 to Evaluate the Immunogenicity and Safety of Recombinant Nonavalent (Types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia Coli)

NCT06207175 is registered in ClinicalTrials.gov with Beijing Health Guard Biotechnology, Inc as lead sponsor.

NCT NCT06207175
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06207175 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Trial in Healthy Indonesian Women Ages 18-45 to Evaluate the Immunogenicity and Safety of Recombinant Nonavalent (Types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia Coli)
Lead sponsor
Beijing Health Guard Biotechnology, Inc
Phase
Phase 3
Overall status
Unknown status
Start date
November 21, 2023
Completion date
January 25, 2026
Enrollment
1,260 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

human papillomavirus infection